Complete Response Letter definition
Examples of Complete Response Letter in a sentence
As disclosed in the SEC Reports, the Company has been informed by the FDA that the FDA will prohibit the marketing, sale, license or commercial use in the United States of a product proposed to be marketed by the Company until certain deficiencies have been addressed as cited in the FDA Complete Response Letter the Company received in December 2023.
On October 25, 2021, the Company announced the reclassification of the Company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, MydCombi, as a drug- device combination product by the FDA in a Complete Response Letter (“CRL”) received on October 22, 2021, following a change in the agency’s legal interpretation of its authorities imposed by a recent court ruling.
A.P. Pharma submitted a New Drug Application (NDA) to the FDA in May 2009 and received a Complete Response Letter in March 2010 that outlined several issues that would need to be addressed prior to FDA approval of APF530.
In December 2019, we submitted a New Drug Application (“NDA”) for IV Tramadol and received a Complete Response Letter (the “First CRL”) from the FDA in October 2020.
A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form.
Portola received a Complete Response Letter from the FDA regarding its Biologics License Application for andexanet alfa in August 2016, and expects to resubmit the application in the first half of 2017.
In June 2018, we received a Complete Response Letter from the FDA for our NDA.
However, in April 2024, the FDA issued a Complete Response Letter (“CRL”) in response to the BLA.
On May 27, 2016, AstraZeneca plc (“AstraZeneca”) announced that the FDA issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for sodium zirconium cyclosilicate (“ZS-9”), an investigational medicine being developed for the treatment of hyperkalaemia by a wholly owned subsidiary of AstraZeneca, communicating its decision that an NDA to market ZS-9 would not be approved in its present form.
A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional Phase III trial or other significant and time-consuming requirements related to clinical trials, non-clinical studies, or manufacturing.